Easing the path for green tech in India

Mark Twain, the US writer, once said “get your facts first, then you can distort them as you please”. Green technologies and patents are at a cross-roads in India, so let’s get our green patent facts first before analysing whether they have been distorted in an endeavour to create a patent-unfriendly climate.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Part I: Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

More features

Part II: The race to replace semaglutide heats up

Part I: Ozempic goes generic as Novo’s key patent expires

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

US firm boosts patent bench with Desmarais hire

J&J unit targets former employee over alleged mass data theft

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Easing the path for green tech in India

More on this story

Editor's picks

Editor's picks

More features